Pharmaceutical companies have long experience in measuring the impact of their business programs. The same should apply to their access-to-medicine efforts
Richard Laing, from the Boston University (BU) School of Public Health and former World Health Organization official, says that many efforts to expand access to medicines fail to gather sufficient evidence on how effective they are. His team at BU recently issued a study highlighting these gaps, and emphasizing the need for companies to better document the impact of their programs.
Novartis reaches agreement with Pakistan to supply medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
May 12, 2017 /3BL Media/ -- We are pleased to announce that Novartis and the Ministry of National Health Services, Regulation and Coordination of the Islamic Republic of Pakistan have signed a Memorandum of Understanding to implement Novartis Access in Pakistan. Novartis Access medicines will be made available to the poorest population through hospitals under the Prime Minister’s National Health Insurance Program.
More than half the ASEAN region’s 630 million people are under age 30. Harald Nusser, Head of Novartis Social Business, says that to fight the rise of chronic disease in South East Asia we need to inform its youth on the importance of healthy lifestyles.
As WEF Africa gets underway, Harald Nusser, Head of Novartis Social Business, emphasizes how novel solutions between the public and the private sector are needed to effectively fight the rising epidemic of chronic diseases in Africa
We all agree we need partnerships between the public and the private sector to meet the Sustainable Development Goals. Public-private partnerships (PPPs) require a better understanding between partners and innovation around institutional structures to ensure accountability, risk and benefit sharing, and value for money. These are fine words but, as the representative of a large, research-based multinational, I have found that things are not always that simple...
Novartis joins more than 20 leading biopharmaceutical companies to launch “Access Accelerated”, a global initiative to further advance access to prevention and care for noncommunicable diseases in low and lower-middle income countries
January 18, 2016 /3BL Media/ - On January 18, 2017 at the World Economic Forum in Davos, Switzerland, Novartis joins more than 20 leading biopharmaceutical companies to launch “Access Accelerated”, a global initiative to further advance access to prevention and care for noncommunicable diseases (NCDs) in low and lower-middle income countries (LICs and LMICs).
Health experts from around the world met on November 29 to discuss ways to tackle an emerging crisis.
December 14, 2016 /3BL Media/ - Chronic conditions such as heart disease and cancer are a growing threat in the world’s poorest countries and public health experts from around the world met on November 29 to explore ways of tackling this silent epidemic. Chronic conditions such as heart disease and cancer are a growing threat in the world’s poorest countries and public health experts from around the world met on November 29 to explore ways of tackling this silent epidemic.
Access to healthcare is making controversial headlines these days as the report of the High-Level Panel on Access to Medicines set up by the Secretary-General of the United Nations was just released. We need to move away from ideological disputes about intellectual property and focus on how we can help patients receive the treatments they need now.
Any solution to the access challenge needs to consider the complex factors that affect access in developing countries. It would indeed be misleading and counter-productive to focus the access debate on patents. (...)